Jessica Fioravanti

Jessica Fioravanti

Auto-generated profile, based on publicly available information

Jessica Fioravanti

Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2019 in Nature Immunology
Verified
Journal Article
Open access
PDF file
CYChen Yao
Chen Yao
HSHong-Wei Sun
Hong-Wei Sun
NLNeal E. Lacey
Neal E. Lacey
YJYun Ji
Yun Ji
EME. Ashley Moseman
E. Ashley Moseman
TWTuoqi Wu
Tuoqi Wu
Progenitor-like CD8+ T cells mediate long-term immunity to chronic infection and cancer and respond potently to immune checkpoint blockade. These cells share transcriptional regulators with memory precursor cells, including T cell-specific transcription factor 1 (TCF1), but it is unclear whether they adopt distinct programs to adapt to the immunosuppressive environment. By comparing the single-cell transcriptomes and epigenetic profiles of CD8+ T cells responding to acute and chronic viral infections, we found that progenitor-like CD8+ T cells became distinct from memory precursor cells before the peak of the T cell response. We discovered a coexpression gene module containing Tox that exhibited higher transcriptional activity associated with more abundant active histone marks in progenitor-like cells than memory precursor cells. Moreover, thymocyte selection-associated high mobility group box protein TOX (TOX) promoted the persistence of antiviral CD8+ T cells and was required for the programming of progenitor-like CD8+ T cells. Thus, long-term CD8+ T cell immunity to chronic viral infection requires unique transcriptional and epigenetic programs associated with the transcription factor TOX.

1 April 2015 in Cell
Verified
Journal Article
Closed access
LGLuca G. Guidotti
Luca G. Guidotti
DIDonato Inverso
Donato Inverso
LSLaura Sironi
Laura Sironi
PLPietro Di Lucia
Pietro Di Lucia
JFJessica Fioravanti
Jessica Fioravanti
MIMatteo Iannacone
Matteo Iannacone

2 March 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DHDalton Hermans
Dalton Hermans
SGSanjivan Gautam
Sanjivan Gautam
JGJuan Carlos Garcia-Cañaveras
Juan Carlos Garcia-Cañaveras
DGDaniel James Gromer
Daniel James Gromer
SMSuman Mitra
Suman Mitra
WLWarren J. Leonard
Warren J. Leonard
Interleukin (IL)-2 and IL-21 dichotomously shape CD8 + T cell differentiation. IL-2 drives terminal differentiation, generating cells that are poorly effective against tumors, whereas IL-21 promotes stem cell memory T cells (T SCM ) and antitumor responses. Here we investigated the role of metabolic programming in the developmental differences induced by these cytokines. IL-2 promoted effector-like metabolism and aerobic glycolysis, robustly inducing lactate dehydrogenase (LDH) and lactate production, whereas IL-21 maintained a metabolically quiescent state dependent on oxidative phosphorylation. LDH inhibition rewired IL-2–induced effects, promoting pyruvate entry into the tricarboxylic acid cycle and inhibiting terminal effector and exhaustion programs, including mRNA expression of members of the NR4A family of nuclear receptors, as well as Prdm1 and Xbp1 . While deletion of Ldha prevented development of cells with antitumor effector function, transient LDH inhibition enhanced the generation of memory cells capable of triggering robust antitumor responses after adoptive transfer. LDH inhibition did not significantly affect IL-21–induced metabolism but caused major transcriptomic changes, including the suppression of IL-21–induced exhaustion markers LAG3, PD1, 2B4, and TIM3. LDH inhibition combined with IL-21 increased the formation of T SCM cells, resulting in more profound antitumor responses and prolonged host survival. These findings indicate a pivotal role for LDH in modulating cytokine-mediated T cell differentiation and underscore the therapeutic potential of transiently inhibiting LDH during adoptive T cell-based immunotherapy, with an unanticipated cooperative antitumor effect of LDH inhibition and IL-21.

18 February 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SGSanjivan Gautam
Sanjivan Gautam
JFJessica Fioravanti
Jessica Fioravanti
WZWei Zhu
Wei Zhu
JGJohn B. Le Gall
John B. Le Gall
PBPhilip Brohawn
Philip Brohawn
LGLuca Gattinoni
Luca Gattinoni

25 February 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
TYTori N. Yamamoto
Tori N. Yamamoto
PLPing-Hsien Lee
Ping-Hsien Lee
SVSuman K. Vodnala
Suman K. Vodnala
DGDevikala Gurusamy
Devikala Gurusamy
RKRigel J. Kishton
Rigel J. Kishton
CKChristopher A. Klebanoff
Christopher A. Klebanoff
Across clinical trials, T cell expansion and persistence following adoptive cell transfer (ACT) have correlated with superior patient outcomes. Herein, we undertook a pan-cancer analysis to identify actionable ligand/receptor pairs capable of compromising T cell durability following ACT. We discovered that FASLG, the gene encoding the apoptosis-inducing ligand FasL, is overexpressed within the majority of human tumor microenvironments (TMEs). Further, we uncovered that Fas, the receptor for FasL, is highly expressed on patient-derived T cells used for clinical ACT. We hypothesized that a cognate Fas-FasL interaction within the TME might limit both T cell persistence and anti-tumor efficacy. We discovered that genetic engineering of Fas variants impaired in the ability to bind FADD functioned as dominant negative receptors (DNRs), preventing FasL-induced apoptosis in Fas-competent T cells. T cells co-engineered with a Fas DNR and either a T cell receptor or chimeric antigen receptor exhibited enhanced persistence following ACT, resulting in superior anti-tumor efficacy against established solid and hematologic cancers. Despite increased longevity, Fas DNR-engineered T cells did not undergo aberrant expansion or mediate autoimmunity. Thus, T cell-intrinsic disruption of Fas signaling through genetic engineering represents a potentially universal strategy to enhance ACT efficacy across a broad range of human malignancies.

21 October 2016 in Science Immunology
Verified
Journal Article
Closed access
SSStefano Sammicheli
Stefano Sammicheli
MKMirela Kuka
Mirela Kuka
PLPietro Di Lucia
Pietro Di Lucia
NONereida Jiménez de Oya
Nereida Jiménez de Oya
MGMarco De Giovanni
Marco De Giovanni
MIMatteo Iannacone
Matteo Iannacone
LCMV evades B cell responses by recruiting inflammatory monocytes to draining lymph nodes. See related Research Articles by Fallet et al. and Moseman et al. and a Focus by Laidlaw et al.